Koshimizu Toshimasa (JAPIC ) DI DI DI DI DI 10

Size: px
Start display at page:

Download "Koshimizu Toshimasa (JAPIC ) DI DI DI DI DI 10"

Transcription

1

2 Koshimizu Toshimasa (JAPIC ) DI DI DI DI DI 10

3 注 DI ISBN p 500

4 (Inoue Shuji) 1 2) ( ) ( ) 1. ( common disease ) 4) 5 10 FDA QOL 3) )BMI 30 BMI 27 ( ) 6,7)

5 HDL- BMI 25 BMI 25 ) 10 2) ( 85cm 90cm ) CT 100cm 2 2) ( ) BMI 30 Pickwick BMI cm ( 2) ( ) 1

6 3 2 ( ) ) Fen-phen 5 6 1

7 3 6) +70% (BMI) mg 1.5 mg 1 (7.1 %) (6.4 %) (4.2 %) (2.1 %) 5 7) MAO 3 Meridia, Reductil Bray 8) mg/ Smith 9) 1 10mg/ 15mg/ 485

8 1 10mg mg 7.3 ( ) ) 4 11) 12) 4 Y

9 4 Y - ciliary neurotrophic factor (Axokine ) 14) 15 16) 4. Xenical FFA 1 120mg A,D,E,K

10 2 300mg 19) 1993 (36.6%) (39.7%) (23.7%) (9.9%) 3.1%) ) mg/ 6 12mg 1 2.5kg UCPs subtype UCP-1 UCP

11 5 10 1) Body mass index, , ) , ) Executive summary of the clinical guidelines on the identification, evaluation,and treatment of overweight and obesity in adults. Arch Intern Med 158:1855, ) Guidance for the clinical evaluation of weight-control drugs, FDAdocuments,No169, ) Connolly HM et al:valvular heart disease associated with fenfluramine phentermine. New Engl J Med 337: , ). 25: , ) Hagiwara M,et al:delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol -A case report Jpn Circ J 64: , ) Bray,GA,et al: Sibutramine produces dose-related weight loss. Obes Res 7: , ) Smith IG: Randomized placebo controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50: , ) Luque CA,et al:sibutramine:a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 33: , ) Zhang Y, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 372: , ) Heymsfield SB.et al: Recombinant leptin for weight loss in obese and lean adults: a randomized,controlled,dose-escalation trial. JAMA 282: , ) Madsbad S,et al:improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting Glucagons-like Peptide 1 analog liraglutide(nn2211). Diabetes Care 27: , ) Lambert PD, et al: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat,without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA.98: , ) Simiand J,et al: SR ,a CB1 cannabinoid receptor antagonist, selectively

12 reduces sweet food intake in marmoset. Behav Pharmacol 9: , ) Trillou CR.et al:anti-obesity effect of SR141716,a CB1 receptor antagonist,in dietinduced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R , ) Finer N,et al.:one year treatment of obesity: a randomised, double-blind, placebocontrolled, multicentre study of orlistat(xenicalr), a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24: , ) Hill JO,et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting. Am J Clin Nutr 69: , ). (NIDDM) BAYg5421(Acarbose) Placebo. 149: , ) -gulucosidase AO : , 1992.

13 10 DB DB CD-ROM , I 100mg 200 g 300mg 5mg 10mg 15mg TEL TEL

14 !! JAPIC CONTENTS!! 16 1 JAPIC Web JAPIC CONTENTS JAPIC CONTENTS 1 Information JAPIC CONTENTS ( ) PDF 1 JAPIC CONTENTS 500 JAPIC JAPIC CONTENTS PDF . tosho@japic.or.jp TEL JAPIC iyakusearch iyakusearch 10 JAPIC TEL

15 5 JAPIC II JAPIC 5 JAPIC JAPIC JAPIC JAPIC 3 3 JAPIC JAPIC iyakusearch JAPIC JAPIC Web iyakusearch EMBASE JAPICDOC JAPIC JAPIC

16 5 JAPIC JAPIC 122 Q A I % 0 25(20.5%) % 1(0.8%) 2. JAPIC % 3. JAPIC % JAPIC JAPICDOC 57 (46.7) 37 (30.3) 2 (1.6) 26 (21.3) JAPICDOC ( 35 (28.7) ) 55 (45.1) 4 (3.3) 28 (22.9) NewPINS 19 (15.5) 56 (45.9) 7 (5.7) 40 (32.8) ADVISE 18 (14.8) 57 (46.7) 7 (5.7) 40 (32.8) SOCIE 17 (13.9) 54 (44.3) 6 (4.9) 45 (36.9) SHOUNIN 8 ( 6.6) 53 (43.4) 12 (9.8) 49 (40.2) MMPLAN 7 (5.7) 60 (49.1) 11 (9.0) 44 (36.1) 85 (69.7) 13 (10.7) 5 (4.1) 19 (15.5) JAPIC NEWS 62 (50.8) 26 (21.3) 1 (0.8) 33 (27.1) JAPIC CONTENTS 59 (48.4) 28 (22.9) 3 (2.5) 32 (26.2) 55 (45.1) 34 (27.9) 2 (1.6) 31 (25.4)

17 45 (36.9) 34 (27.9) 6 (4.9) 37 (30.3) JAPIC 37 (30.3) 44 (36.1) 4 (3.3) 37 (30.3) 33 (27.0) 42 (34.4) 11 (9.0) 36 (29.5) 20 (16.4) 50 (40.9) 6 (4.9) 46 (37.8) Regulations View 18 (14.8) 40 (32.8) 19 (15.5) 45 (36.9) 16 (13.1) 58 (47.5) 5 (4.1) 43 (35.2) JAPIC CONTENTS Web 11 (9.0) 50 (41.0) 13 (10.7) 48 (39.3) JAPIC ( ) 11 (9.0) 51 (41.8) 14 (11.5) 46 (37.7) 52 (42.6) 29 (23.8) 8 (6.6) JAPIC Q 33 (27.0) JAPIC Daily Mail 47 (38.5) 34 (27.9) 9 (7.4) 32 (26.2) 29 (23.8) 48 (39.3) 4 (3.3) 41 (33.6) JAPIC Q Plus 16 (13.1) 45 (36.9) 13 (10.7) 48 (39.3) JAPIC Daily Mail Plus 17 (13.9) 44 (36.1) 13 (10.7) 48 (39.3) PubMed 8 (6.6) 53 (43.4) 11 (9.0) 50 (41.0) SGML PDF 8 (6.6) 53 (43.4) 11 (9.0) 50 (41.0) 4. JAPIC 13 iyakusearch TEL

18 JASDI JAPIC NewPINS JAPICDOC JAPIC NewPINS JAPIC

19 NewPINS 2004/02/26 12,356 7,547 JAPIC 143,757 JAPIC 108, , JAPIC 6, ,035 4 AST(GOT) ALT(GPT) Al-P -GTP JAPIC 76 JAPIC NewPINS JAPICDOC JAPIC MedDRA JART

20 1 JAPIC JAPIC :30 15:00 3 PhaRMA 30 JAPIC TEL ( ) TEL

21

22 9,608 3,874 USAN( )

23 JAPIC IT JAPIC JAPIC iyakusearch 3

24 TEL Regulations View No.107. JAPIC CONTENTS No No JAPIC NEWS No.244. DB FAX No JAPIC-Q. JAPIC-Q Plus. JAPIC Daily Mail No JAPIC Daily Mail Plus No PubMed

25 JIP JIP e-infostream. JAPICDOC JAPICDOC ADVISE MMPLAN 7 9. SOCIE. NewPINS. SHOUNIN <JST JOIS > JAPICDOC 7 TEL

26 JAPIC JAPIC NEWS No ( 1 ) TEL 03(5466)1811 FAX 03(5466)1814

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

2007050781......_.L.O...z.W

2007050781......_.L.O...z.W a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

More information

2001 2003 2005 2006 2007 2008

2001 2003 2005 2006 2007 2008 2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65

More information

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate 37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

More information

BAANs理論に基づく保健指導プログラム暫定版

BAANs理論に基づく保健指導プログラム暫定版 WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal

More information

The Heart Healthy Tocotrienol Complex Tocomin SupraBio

The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation

More information

268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb

268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb 52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2

More information

1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,

More information

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

More information

VOL33NO.3/2010 A B A B p-erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 Erk1/2 Time (min) 0 1 2 5 10 15 30 60 90 120 p-vasp VASP C D enos/gapdh x-fold vs sham 2.0 1.5 1.0 0.5 * 0 ANP (-) (+) (-)

More information

第124回日本医学会シンポジウム

第124回日本医学会シンポジウム IV β Therapeutic approaches to obesity HIRONOBU YOSHIMATSU Department of Internal Medicine 1, Faculty of Medicine, Oita University Key words 124 124 1,2 BAT uncoupling protein 1UCP1 1,3 A 1 α-fluoromethylhistidinefmh

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 µ µ µ 14 15 16 17 1. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M: Development of type 1 diabetes mellitus during interferon alfa

More information

2009年133巻3号3月号.indb

2009年133巻3号3月号.indb Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine

More information

JHN Journal Club 手稲渓仁会病院

JHN Journal Club 手稲渓仁会病院 JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c

More information

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ 29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27

More information

untitled

untitled ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504

More information

Microsoft Word - 「黄砂とその健康影響について」小冊子180323版

Microsoft Word - 「黄砂とその健康影響について」小冊子180323版 ...1...1...1...2...4...4...4...6...7...7...7...7...8...8...9...9...10... 11... 11... 11... 11...12...12...13...16...18...20 1 1-1 1-2 1 1 km 24.5 m/s 10 50 m 1 1-3 μm 1-4 1-5 2 8 http://www.jma-net.go.jp/sat/himawari/obsimg/image_dust.html

More information

http://www.med.tohoku.ac.jp/st udy_room/13/index.html 263-6931 http://www.pharmac... http://www.www.com//dtd html 4.0 transitional//en HEALTH & MEDICINE Nutrition, Pharmacy, Fitness, Woman's Health, Weight

More information

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2 2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.

More information

Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : takaiwa@nias.affrc.go.jp 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.

More information

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です 8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%

More information

食道がん化学放射線療法後のsalvage手術

食道がん化学放射線療法後のsalvage手術 2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573

More information

1315 (15)

1315 (15) (14) 1315 (15) 1316 (16) 1317 (17) 1318 (18) 1319 (19) 1320 (20) 1321 (21) 1322 quinidine, disopyramide, and procainamide in isolated atrial myocytes : Mediation by 2) Inoue H, et al: Effects of pentisomide

More information

第124回日本医学会シンポジウム

第124回日本医学会シンポジウム III γ γ γ α γ Molecular Mechanism of Insulin Resistance by Adipocytes TAKASHI KADOWAKI Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo Key words γ 110 124 TNFα FFA 1,2

More information

(Pantothenic acid, C 9 H 17 NO 5, MW: CH 3 OH HOCH 2 C CHCONHCH 2 CH 2 COOH CH 3 (Calcium pantothenate, C 18 H 32 CaN 2 O 10, MW: ) CH 3

(Pantothenic acid, C 9 H 17 NO 5, MW: CH 3 OH HOCH 2 C CHCONHCH 2 CH 2 COOH CH 3 (Calcium pantothenate, C 18 H 32 CaN 2 O 10, MW: ) CH 3 (Pantothenic acid, C 9 H 17 NO 5, MW: 219.24 CH 3 OH HOCH 2 C CHCONHCH 2 CH 2 COOH CH 3 (Calcium pantothenate, C 18 H 32 CaN 2 O 10, MW: 476.54) CH 3 CH 3 OH HOOC 2 HC 2 HCHNOCHC C OCH 2 Ca OCH 2 C CHCONHCH

More information

第79回_プログラム.indd

第79回_プログラム.indd Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial

More information

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9 32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5

More information

An effect of nutritional lectures and practicum on the mental health and health habits of vocational college students Kanae SATO14, Michiko HARAZ, Tsu

An effect of nutritional lectures and practicum on the mental health and health habits of vocational college students Kanae SATO14, Michiko HARAZ, Tsu An effect of nutritional lectures and practicum on the mental health and health habits of vocational college students Kanae SATO14, Michiko HARAZ, Tsukasa MURAMATSU3 and Hiko TAMASHIRO4 We conducted two

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

sick contact1l

sick contact1l Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5

More information

BMI18 1

BMI18 1 The role of nutrition intervention for increasing body weight in college girls with BMI less than 18. Yukiko Miyake BMI18 1 BMI18 1950 2 1/10 2007 1 14 NY DSMIV WHO ICD101992 2 17 20 BMI18.5 22.6 21 21

More information

C/NC : committed/noncommitted

C/NC : committed/noncommitted C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a

More information

日本皮膚科学会雑誌第122巻第2号

日本皮膚科学会雑誌第122巻第2号 J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot

More information

胆石症

胆石症 ,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic

More information

untitled

untitled Fig.1 t O O N,N p n J J J J J t J J J J J J J J J J J t t J J J J J J J J J p Fig.2 p t Fig.3 Fig.4 synanti p Table1 Table2t Table2 synanti antisyn synanti synanti Fig.5 syn anti anti Fig.6 Table3 Table4

More information

1) Lysozyme and Viral Infections, 2nd Intern- Symposium on Fleming's Lysozyme, ational Milano, Apr. 1961. 2) Ermol'eva, Z.V. et al.: Experimental study and clinical application of lysozyme. Fed. Proc.

More information

.K.C.h...C...ren

.K.C.h...C...ren 4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200

More information

1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%

More information

5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p

More information

Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,

More information

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

More information

WHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support

More information

24,828,330 Contents 9,931,332 8,223,840 3,436,978 9,931,332 7,674,406 3,413,724 2,985,287 1

24,828,330 Contents 9,931,332 8,223,840 3,436,978 9,931,332 7,674,406 3,413,724 2,985,287 1 24,828,330 Contents 9,931,332 8,223,840 3,436,978 9,931,332 7,674,406 3,413,724 2,985,287 1 2 3 1Chapter 138 4 5 Case Study 1 Case Study 2 6 Case Study 4 7 Case Study 3 9 Case Study 6 Case Study 5 8 10

More information

小児感染免疫第23巻第1号

小児感染免疫第23巻第1号 Vol. 23No. 163 42 HPV HPV 1113 HPV 42 HPV HPV HPV 1 1 510 1020 HPV 1020 510 HIV 0.1 0.005 HIV 2030 HIV 0.2 510 HPV 1020 15 HIV 2030 HIV HIV 0.2 0.1 Takeyuki Sato 2608677 181 64 2011 2 1 1518 6,000 513

More information

‰Łflç‘ÇŁ\”ƒ(’FŁª›ð)-A4

‰Łflç‘ÇŁ\”ƒ(’FŁª›ð)-A4 1 14163 1611 (2002) 32007 3 3 196 2 1416 ( ) Medsger modified Rodnan total skin thickness score EBM placebo control ACEEBM EBM 3 1611 4 5 (Systemic Sclerosis : SSc) 1980 (1) 1) 200310 (2) 2003 Scl-70 1

More information

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%

More information

橡

橡 TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1

More information

日本皮膚科学会雑誌第121巻第11号

日本皮膚科学会雑誌第121巻第11号 β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis

More information

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ , 24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998

More information

body size no effect mechanical stress GH-IGF1 system + no effect? collagen production of fibroblasts + receptor + + Ia, Ib, II aldosterone renin angiotensin system Mechanical and Endocrinological

More information

P.37 P.816 P.17 P.1819 contents 1 2

P.37 P.816 P.17 P.1819 contents 1 2 201211 NEW! P.37 P.816 P.17 P.1819 contents 1 2 3 4 5 6 7 8 http://www.tokiomarine-nichido.co.jp/ 1 2 16 3 11 4 1 18 9 10 5 6 11 12 18 9 10 6 7 8 13 1411 12 5 13 14 15 1615 16 21 17 18 0120-071-281 19

More information

「消える」金融、「創る」金融-2010年のリテール金融

「消える」金融、「創る」金融-2010年のリテール金融 2010 2010 CONTENTS 1 2 3 4 18 20066 1 2 19 20 20066 3 1 12 21 2 22 20066 3 4 23 1 1997 1997 1984 1893 1983 1980 2001 1990 1990 24 20066 1 260 26,418 213,597 239,416 1720062 25 2 3 26 20066 3 5 27 4 4 44

More information

drug development Toshimi Michigami, E-mail : michigami@mch.pref.osaka.jp Keiichi Ozono, E-mail : keioz@ped.med.osaka-u.ac.jp The progress in the research on vitamin D 1) McCollum, E. V. et al.:

More information

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10 163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination

More information

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01 2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation

More information

日本皮膚科学会第121巻第9号

日本皮膚科学会第121巻第9号 Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev

More information

untitled

untitled CoQ10 CoQ10 CoQ10 CoQ10 CoQ10 (A CoQ10 CoQ10 B CoQ10 CoQ10 C CoQ10 CoQ10 CoQ10 QOL CoQ10 QOL CoQ10 CoQ10 CoQ10 CoQ10 14 還元型 CoQ10 の摂取はインフルエンザウイルス感染に対する予防効果を示す CoQ1050CoQ10 CoQ1080CoQ10 Åberg et al., Arch

More information

untitled

untitled ( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m

More information

本 リポートは 第 63 回 定 例 研 究 会 の 研 究 報 告 の 速 記 録 をもとに 作 成 したものです < 本 リポートのキーワード> メタボリックシンドローム 内 臓 脂 肪 生 活 習 慣 病 特 定 健 康 診 査 特 定 保 健 指 導 減 量 肥 満 ( 注 ) 本 リポート

本 リポートは 第 63 回 定 例 研 究 会 の 研 究 報 告 の 速 記 録 をもとに 作 成 したものです < 本 リポートのキーワード> メタボリックシンドローム 内 臓 脂 肪 生 活 習 慣 病 特 定 健 康 診 査 特 定 保 健 指 導 減 量 肥 満 ( 注 ) 本 リポート ARCリポート (RS 8 7 2) 禁 複 製 社 内 限 り 第 63 回 定 例 研 究 会 研 究 報 告 ライフサイエンスシリーズ メタボリックシンドローム 対 策 について 日 本 は 経 済 成 長 保 健 医 療 のレベルアップを 背 景 に 世 界 で トップレベルの 長 寿 国 になってきた 一 方 便 利 さや 豊 かさの 裏 腹 として 運 動 不 足 や 摂 取 カロリー

More information

H1.eps

H1.eps Contents 1 4 Section 1 7 1 2 3 8 14 21 Section 2 27 1 2 3 28 34 40 Section 3 43 1 2 3 44 49 57 Section 4 63 1 2 3 4 5 64 72 77 84 88 96 Prologue Prologue S e c t i o n 1 1 8 S e c t i o n1 9 1 10 S e

More information

untitled

untitled COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5

More information

慢性膵炎

慢性膵炎 - - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider

More information

bc0710_010_015.indd

bc0710_010_015.indd Case Study.01 Case Study.02 30 Case Study.05 Case Study.03 Case Study.04 Case Study.06 Case Study.07 Case Study.08 Case Study.21 Case Study.22 Case Study.24 Case Study.23 Case Study.25 Case Study.26

More information

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1 11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

More information

2 3 Q1 Q3 Q4 Q2

2 3 Q1 Q3 Q4 Q2 MARCH 2012 vol. 221 3 02 04 CONTENTS 08 10 Concert Report 11 12 NEWS Index 14 CAMPUS Information 15 Information 16 2 3 Q1 Q3 Q4 Q2 4 5 n u m b e r 0 3 6 7 n u m b e r 0 4 8 9 Concert Report Topics 01 Topics

More information

日本皮膚科学会雑誌第120巻第5号

日本皮膚科学会雑誌第120巻第5号 1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3

More information

終末期癌患者に対する 輸液治療の是非

終末期癌患者に対する 輸液治療の是非 3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p

CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure parameters during the diet and lifestyle improvement

More information

180 140 22

180 140 22 21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3

More information

4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.

More information

<82D282A982C1746F95F18D908F57967B95B E696E6464>

<82D282A982C1746F95F18D908F57967B95B E696E6464> 1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9

More information

6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61

More information

[] 1

[] 1 0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2

More information

7) G. N., A. A. Sondore et al.: The Use of Hyperbaric Oxygenation in Intensive Therapy of Patients with Liver Damage. VI Int. Cong. HBO Medicine, Moscow, Sept 2 `6:341, 1981 8) J. J. Moder, M. D.: Phagocytic

More information

NAVIGATION MD Consult MD Consult Home home Books Book List page Journals Journal Search page Drugs Drug Look-up:Drug UpdatesDrug Information News This

NAVIGATION MD Consult MD Consult Home home Books Book List page Journals Journal Search page Drugs Drug Look-up:Drug UpdatesDrug Information News This NAVIGATION...2 BOOKS...4 JOURNALS...5 DRUGS...8 NEWS...8 NEWS...9 CURRENT PRACTICE...10 PATIENT HANDOUTS...11 LEARNING CENTER...12 Search...13 My Folder...14 1 NAVIGATION MD Consult MD Consult Home home

More information

untitled

untitled 2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.

More information

21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony

More information

SBP hospitalist network.key

SBP hospitalist network.key 1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous

More information

PubMedとは

PubMedとは 7 1 PubMed 1994 4 1999 4 2004 4 7 PubMed PubMed http://www.ncbi.nlm.nih.gov/pubmed/ http://pubmed.gov National Library of Medicine; NLM PubMed NLM MEDLINE MEDLINE Index Medicus PubMed PubMed 1879 1964

More information

別紙様式 (Ⅵ)-2 商品名 : エクササイズダイエット 届出食品に関する表示の内容 科学的根拠を有する機能性関与成分名及び当該成分又は当該成分を含有する食品が有する機能性一日当たりの摂取目安量 本品には 3% グラブリジン含有甘草抽出物が含まれます 3% グラブリジン含有甘草抽出物は 肥満気味の方

別紙様式 (Ⅵ)-2 商品名 : エクササイズダイエット 届出食品に関する表示の内容 科学的根拠を有する機能性関与成分名及び当該成分又は当該成分を含有する食品が有する機能性一日当たりの摂取目安量 本品には 3% グラブリジン含有甘草抽出物が含まれます 3% グラブリジン含有甘草抽出物は 肥満気味の方 別紙様式 (Ⅳ) 商品名 : エクササイズダイエット 健康被害の情報収集体制 健康被害の情報の対応 窓口部署名等 株式会社ディーエイチシー 健康食品相談室 電話番号 0120-575-368 ファックス番号電子メールその他連絡対応日時 ( 曜日 時間等 ) FAX による受付は行っていない電子メールによる受付は行っていない該当なし 9 時 ~20 時 ( 日 祝をのぞく ) 該当なし その他必要な事項

More information

J. Jpn. Acad. Nurs. Sci. 32(3): (2012)

J. Jpn. Acad. Nurs. Sci. 32(3): (2012) J. Jpn. Acad. Nurs. Sci., Vol. 32, No. 3, pp. 74 84, 2012 Development and Effectiveness of a Dietary Education Program for Patients with Crohns Disease 1 2 2 2 Maya Nunotani, Yayoi Kamakura, Junko Fukada,

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

Effects of Diet Class on Overweight Middle-aged Women Analysis of Nutritional Intake Pattern YAMAGUCHI Shizue*, MATSUMOTO Tomoko**, MIMURA Kan-ichi***, ASAI Hitoshi****, OKUDA Toyoko***** * O saka Shin-ai

More information

untitled

untitled ... 4...5...6...7...10...11... 12...12...12...13...14...15...15...16...16...17...17...18...18...19...19...19 Hill...20...20...21...21...22...23...24...25... 34...34...35...38-2 - ...41...49...51...51...51...52...53...56...56...57...60...60-3

More information

感覚系における人工臓器 ─人工網膜

感覚系における人工臓器 ─人工網膜 人工臓器 最近の進歩 Hiroyuki KANDA, Takashi FUJIKADO 1. はじめに 2. 視覚のなり立ち 図 1 10 著者連絡先 565-0871 2-2 E-mail. kanda@sensory.med.osaka-u.ac.jp 1 3. 視覚障害 Quality of Life QOL 2 1 1 12 18 1 25.5 2 21.0 3 8.8 1) 1 51 New

More information